T 1253/23 (Immune response to natalizumab/BIOGEN) of 16.12.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T125323.20251216
- Date of decision
- 16 December 2025
- Case number
- T 1253/23
- Petition for review of
- -
- Application number
- 17174144.0
- IPC class
- G01N 33/68
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Methods for evaluating an immune response to a therapeutic agent
- Applicant name
- Biogen MA Inc.
- Opponent name
- Polpharma Biologics S.A.
- Board
- 3.3.08
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(c)European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 56European Patent Convention Art 76(1)European Patent Convention R 103(1)(a)
- Keywords
- Grounds for opposition - added subject-matter (yes)
Amendments - extension beyond the content of the application as filed (yes)
Amendments - broadening of claim (yes)
Divisional application - subject-matter extends beyond content of earlier application (yes)
Inventive step - obvious solution
Substantial procedural violation - reimbursement of appeal fee (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.
3. The appeal fee of appellant II is reimbursed.